NR3C2 and type 2 diabetes mellitus: Potential therapeutic agents are glucagon-like peptide-1 receptor (GLP-1) agonists, mineralocorticoid receptor blockers such as eplerenone, and fenofibrate, which have been shown to reduce myocardial steatosis in Type 2 Diabetes [33, 39, 40].